Targeted microbubbles: a novel application for the treatment of kidney stones
Abstract
Kidney stone disease is endemic. Extracorporeal shockwave lithotripsy was the first major technological breakthrough where focused shockwaves were used to fragment stones in the kidney or ureter. The shockwaves induced the formation of cavitation bubbles, whose collapse released energy at the stone, and the energy fragmented the kidney stones into pieces small enough to be passed spontaneously. Can the concept of microbubbles be used without the bulky machine? The logical progression was to manufacture these powerful microbubbles ex vivo and inject these bubbles directly into the collecting system. An external source can be used to induce cavitation once the microbubbles are at their target; the key is targeting these microbubbles to specifically bind to kidney stones. Two important observations have been established: (i) bisphosphonates attach to hydroxyapatite crystals with high affinity; and (ii) there is substantial hydroxyapatite in most kidney stones. The microbubbles can be equipped with bisphosphonate tags to specifically target kidney stones. These bubbles will preferentially bind to the stone and not surrounding tissue, reducing collateral damage. Ultrasound or another suitable form of energy is then applied causing the microbubbles to induce cavitation and fragment the stones. This can be used as an adjunct to ureteroscopy or percutaneous lithotripsy to aid in fragmentation. Randall's plaques, which also contain hydroxyapatite crystals, can also be targeted to pre-emptively destroy these stone precursors. Additionally, targeted microbubbles can aid in kidney stone diagnostics by virtue of being used as an adjunct to traditional imaging methods, especially useful in high-risk patient populations. This novel application of targeted microbubble technology not only represents the next frontier in minimally invasive stone surgery, but a platform technology for other areas of medicine.
Additional Information
© 2014 The Authors BJU International. © 2014 BJU International Published by John Wiley & Sons Ltd. Conflicts of Interest: D.L. reports personal fees from Applaud Medical, Inc. outside the submitted work. M.L.S. reports having a patent Provisional Patent pending. R.H.G. reports having a patent Provisional Patent.Attached Files
Accepted Version - nihms682638.pdf
Supplemental Material - bju12996-sup-0001-VideoS1.mp4
Supplemental Material - bju12996-sup-0002-VideoS2.mp4
Files
Name | Size | Download all |
---|---|---|
md5:7c7a95cae80c72cf7b76bf71784499e6
|
103.3 kB | Download |
md5:24d32b093896c3a6c5cfc22c39bb34b5
|
556.4 kB | Preview Download |
md5:a39c1e82c70d9981a8ecff552cb486f5
|
113.5 kB | Download |
Additional details
- PMCID
- PMC4433869
- Eprint ID
- 58962
- Resolver ID
- CaltechAUTHORS:20150721-105930597
- Created
-
2015-07-21Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field